Eli Lilly has received FDA approval for its Alzheimer’s blood test, Elecsys pTau181, designed for patients aged 55 and older. The test enables faster and more accessible diagnoses, facilitating earlier treatment interventions with therapies such as Kisunla, and potentially improving patient outcomes.

In related developments, Aspen Pharmacare has obtained approval to market Eli Lilly’s Mounjaro for weight management in South Africa, following its previous approval for Type 2 diabetes. Mounjaro now competes with Novo Nordisk’s Wegovy in the growing obesity treatment market, highlighting Eli Lilly’s expanding footprint in metabolic and neurodegenerative therapies.

These approvals underscore Eli Lilly’s commitment to innovative diagnostics and therapeutic solutions across multiple high-impact disease areas.